SCHEMBL23715134

SCHEMBL23715134

CC1(C)COCc2ccc(C(=O)O)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 11/20 0.46
RARG P13631 10/20 0.46
RARA P10276 9/20 0.46
CYP26A1 O43174 2/20 0.46
CYP26B1 Q9NR63 1/20 0.46
RXRA P19793 10/20 0.45
RXRB P28702 7/20 0.45
RXRG P48443 5/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30042059 0.86 CA12 (0.42) RARBRARGRARACYP26A1CYP26B1
SCHEMBL23705335 0.86 CA12 (0.42) RARBRARGRARACYP26A1CYP26B1
SCHEMBL30041877 0.86 CA12 (0.42) RARBRARGRARACYP26A1CYP26B1
SCHEMBL23705985 0.86 CA12 (0.42) RARBRARGRARACYP26A1CYP26B1
SCHEMBL23706214 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1
SCHEMBL31396088 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1
SCHEMBL30042430 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1
SCHEMBL23704836 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1
SCHEMBL23704775 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1
SCHEMBL30041409 0.84 RARB (0.44) RARBRARGRARACYP26A1CYP26B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RARB 140/4885RARG 308/4885RARA 393/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RARB 140/4885RARG 308/4885RARA 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.